secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clovis Oncology, Inc. (—)
CIK:        0001466301
Form:       8-K
Filed at:   2023-07-11T23:59:59+00:00
Accession:  0001193125-23-185076
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 1.03, 3.03, 5.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clovis Oncology Chapter 11 plan effective; common stock canceled, no equity recovery expected
--------------------------------------------------------------------------------

- Effective July 10, 2023, Third Amended Joint Chapter 11 Plan of Liquidation became effective.
- All outstanding common stock canceled; no payment or distribution to equity holders anticipated.
- Directors and officers discharged and terminated as of the Effective Date.
- Company intends to file Form 15 to deregister securities and suspend SEC reporting.
- Liquidation Trustee appointed; contingent value rights possible only if creditors paid in full (>$250k).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1466301/000119312523185076/0001193125-23-185076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1466301/000119312523185076/d514612d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-185076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer